id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-3575-0004,FDA,FDA-2025-P-3575,"Letter from FDA CDER to Senores Pharmaceuticals, Inc.",Other,Letter(s),2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-19T17:06:15Z,,0,0,09000064b91bace6
FDA-2025-P-3575-0003,FDA,FDA-2025-P-3575,"Determination That TOLECTIN DS (Tolmetin Sodium) Capsule, Equivalent to 400 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-02-18T05:00:00Z,2026,2,,,2026-02-18T19:03:46Z,2026-03213,0,0,09000064b91b901e